Phaseline

Targets › GPNMB

GPNMB (Transmembrane glycoprotein NMB): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Dec 2028.

Could be a melanogenic enzyme. (UniProt, Q14956)

Open in Phaseline: the race on GPNMB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Canadian Cancer Trials GroupGCAR1
anti-GPNMB CAR-T cell therapy
GPNMBPhase 1Alveolar Soft Part SarcomaDec 2028

Conditions

Alveolar Soft Part Sarcoma (1)

Modalities

mixed (1)

Companies

Canadian Cancer Trials Group (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.